Following a year of turmoil and repair, 1998 will be the most criticalyear in the life of Pharmacia & Upjohn, according to chief executive Fred Hassan. Addressing a recent analysts' meeting in New York, Mr Hassan said that within the next three years, having put in place new strategies and structures for growth, P&U will accomplish its goals and create high-performance results.
Reflecting on his first six months as chief executive, Mr Hassan said that he had found lots of positives and more challenges than he had expected, but soon realized that certain early action was needed, including the simplification of the company's organization and targeting the US market (Marketletters passim).
Mr Hassan added that the USA accounts for 60% of the worldwide drugs market, and P&U had not been getting its fair share of the profits. Currently, Europe accounts for 45% of P&U sales, with 30% in the USA and 12% in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze